The tesamorelin label excludes treatment for anyone who is pregnant, has active cancer or has a known allergy to any ingredient in the medicine.
It also rules out treatment when the system that releases growth hormone has been damaged or disrupted.
Removal of the gland that releases growth hormone is one example; that gland no longer working properly is another. That system can also be disrupted by a tumour, an operation, radiation directed at the head, or an injury to the head.
Bring the doctor a record of your health history along with a list of medicines. Ask whether any past illness or injury affected this system; you do not have to work that out yourself.
What follow-up needs to watch
Tesamorelin can raise blood sugar and IGF-1, a chemical message that helps the body’s cells grow.
The label asks the doctor prescribing the medicine to check blood sugar before treatment and over time, and to check IGF-1 during treatment.
It also calls for review of past cancer and for checks for eye damage in patients with diabetes.
What problems were reported
The label lists reactions at the injection site, joint pain, muscle aches and swelling among reported side effects.
It warns about allergic reactions and fluid retention—when the body holds extra fluid.
Ask which changes call for a prompt call and who answers between visits. Ask for that plan in writing.
When an allergic reaction needs urgent help
Trouble breathing or swelling of your face or tongue can be warning signs that an allergic reaction is severe.
For severe allergic symptoms, MedlinePlus recommends a call to 911 or an immediate trip to the nearest emergency room.
Read the source notes
Source-check dates: September 17, 2026 / September 28, 2026.
- DailyMed: the tesamorelin (EGRIFTA WR) label
- DailyMed: the tesamorelin (EGRIFTA SV) label
- MedlinePlus: severe allergic reactions
Ask for confirmation of the current product, rules and costs before deciding on care.